

Long non-coding RNA *TUSC7* acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma

Yufeng Wang¹ · Zhikui Liu¹ · Bowen Yao¹ · Changwei Dou¹ · Meng Xu¹ · Yumo Xue¹ ·
Linglong Ding¹ · Yuli Jia¹ · Hongyong Zhang¹ · Qing Li¹ · Kangsheng Tu¹ ·
Yang Jiao^{2,3} · Qingguang Liu¹ · Cheng Guo¹

Received: 18 November 2015 / Accepted: 19 January 2016 / Published online: 22 March 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Despite advances in the roles of long non-coding RNA (lncRNA) tumor suppressor candidate 7 (*TUSC7*) in cancer biology, which has been identified as a tumor suppressor by regulating cell proliferation, apoptosis, migration, invasion, cell cycle, and tumor growth, the function of *TUSC7* in hepatocellular carcinoma (HCC) remains unknown. In this study, we observed that the expression of *TUSC7* was immensely decreased in HCC. Clinically, the lower expression of *TUSC7* predicted poorer survival and may be an independent risk factor for HCC patients. Moreover, *TUSC7* inhibited cell metastasis, invasion, and epithelial-to-mesenchymal

transformation (EMT) through competitively binding miR-10a. Furthermore, we found that *TUSC7* could decrease the expression of Epidermal growth factor receptor A4 (*EphA4*), a downstream target of miR-10a as well as an EMT suppressor, through *TUSC7*-miR-10a-*EphA4* axis. Taken together, we demonstrate that *TUSC7* suppresses EMT through the *TUSC7*-miR-10a-*EphA4* axis, which may be a potential target for therapeutic intervention in HCC.

Keywords *TUSC7* · miR-10a · *EphA4* · EMT · HCC

Yufeng Wang and Zhikui Liu contributed equally to this work.

✉ Qingguang Liu
liuqingguang@vip.sina.com

✉ Cheng Guo
guocheng1977@yahoo.com.cn

Yufeng Wang
yfwang441400@126.com

Zhikui Liu
liuzhikui1234@163.com

Bowen Yao
yao_bowen123@126.com

Changwei Dou
doucw567148@qq.com

Meng Xu
xm19912015@163.com

Yumo Xue
729965761@qq.com

Linglong Ding
daw880610laf@126.com

Yuli Jia
winy96@163.com

Hongyong Zhang
zhang_hong_yong@126.com

Qing Li
yuboya0910@126.com

Kangsheng Tu
tks0912@foxmail.com

Yang Jiao
867239355@qq.com

¹ Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China

² Department of Prosthodontics, State Key Laboratory of Military Stomatology, School of Stomatology, The Fourth Military Medical University, Xi'an, People's Republic of China

³ Shaanxi Key Laboratory of Military Stomatology, Xi'an, Shaanxi, People's Republic of China

Introduction

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the second leading cause of death from cancer worldwide [1]. Currently, the prognosis for HCC patients remains poor, with a 5-year survival rate of approximately 30 % after liver resection, which is considered to be the best therapeutic strategy to treat HCC [2]. Local and systemic metastases are the main reasons for the unsatisfactory prognosis of HCC patients [3]. Elucidating the underlying molecular mechanisms for HCC metastasis is critical for identifying novel therapeutic targets of HCC.

Epithelial-to-mesenchymal transformation (EMT) has been widely accepted as a key mechanism underlying the metastatic process of HCC [4]. During the development of EMT, the expressions of epithelial markers such as E-cadherin, zonula occludens-1, and claudins decrease while the expressions of mesenchymal markers such as vimentin, N-cadherin, and fibronectin increase [5]. The EMT process in HCC cells can be regulated by various factors, including hypoxia [6], cytokines [7], long non-coding RNAs (lncRNAs) [8], microRNAs [9], and so on, and targeting the EMT process has been found to be an attractive and promising strategy to prevent the metastasis of HCC [7].

lncRNAs are RNA molecules over 200 nucleotides in length with little protein-coding potential [10]. Previous studies have shown that aberrant lncRNA expression is observed in human cancers, including those in the liver [11], breast [12], colon [13], ovary [14], pancreas [15], and bladder [16]. lncRNAs have been identified with oncogenic properties (*KRAS*, *HULC*, *HOTAIR*, *MALAT1*, *HOTTIP*, *ANIL*, and *RICTOR*) or oncosuppressive properties (*MEG3*, *AS5*, *lincRNA-p21*, *PTENP1*, *TERRA*, *CCND1/CyclinD1*, and *TUG1*) or both (*CCAT1* and *XIST*) [17, 18]. Tumor suppressor candidate 7 (*TUSC7*), also called LOC285194 or *LSAMP* antisense RNA3, is an lncRNA consisting of four exons of more than 2 kb in length and is located at 3q13.31 [19]. Recent studies indicated that lncRNA-*TUSC7* is downregulated in cancers including gastric cancer [20], osteosarcoma [21], colorectal cancer (CRC) [22], esophageal squamous cell carcinoma (ESCC) [23], and so on. In gastric cancer, *TUSC7* is a p53-regulated tumor suppressor that acts in part by repressing miR-23b to suppress tumor cell growth in vitro and in vivo [20]. In osteosarcoma, depleting *TUSC7* promoted proliferation of normal osteoblasts by regulating apoptotic and cell cycle transcripts as well as the vascular endothelial growth factor (VEGF) receptor 1 [21]. In human pancreatic ductal adenocarcinoma (PDAC) and CRC, by analyzing the association of *TUSC7* expression with clinicopathologic features, it was found that low *TUSC7* expression was closely correlated with lymph node metastasis, liver metastasis, and more distant metastases [19, 22]. These data validated that *TUSC7* is a tumor suppressor by regulating cell proliferation, apoptosis,

migration, invasion, cell cycle, and tumor growth. However, the exact role of *TUSC7* in HCC progression and the underlying mechanisms remain unknown.

MicroRNAs (miRNAs) are an abundant group of endogenous non-coding single-strand RNAs, and it is known that aberrant miRNA expression profiles are causally connected to tumor progression [24]. Recently, the competing endogenous RNA (ceRNA) hypothesis proposed that a large number of non-coding RNAs might function as molecular sponges for miRNAs and, hence, functionally liberate other RNA transcripts targeted by the aforementioned active miRNAs [25]. For example, lncRNA-*UCA1* has been reported to play an oncogenic role in breast cancer through directly interacting with miR-143 to lower its expression and affect its downstream regulation [26]. miR-222 could be downregulated by lncRNA-Gas5 in glioma, thereby suppressing the tumor malignancy [27, 28], and has been reported to play critical roles in the development of a variety of human cancers [29–31], including HCC [28, 32]. In HCC, acting as a tumor promoter, the expression of miR-10a has been shown to be upregulated, which accelerates cell migration, invasion, and EMT [32, 33]. Additionally, Erythropoietin receptor tyrosine kinase A4 (*EphA4*), a member of the Eph receptor tyrosine kinase family, has been identified as an EMT suppressor in cancers [34–36]. It is reported that miR-10a could regulate the EMT process in HCC through directly binding the 3'-untranslated region (UTR) of the *EphA4* transcript [32]. However, limited knowledge is available concerning whether *TUSC7* could act as a sponge for miR-10a to affect the biological processes of HCC and the potential primary mechanism among *TUSC7*, miR-10a, and *EphA4* in HCC progression remains unknown.

In this study, we found that the expression of *TUSC7* was decreased in HCC and that *TUSC7* may be a promising prognostic or progression marker for HCC. Additionally, *TUSC7* suppressed cell migration, invasion, and EMT of HCC cells. Moreover, mechanistic analysis revealed that *TUSC7* may function as a ceRNA for miR-10a to regulate the expression of *EphA4* to suppress EMT in HCC, thus playing an oncosuppressive role in HCC pathogenesis. Here, we provide the first evidence for the *TUSC7*-miR-10a-*EphA4* axis, shedding new light on the mechanism of HCC.

Materials and methods

Clinical samples

HCC samples were collected from 75 patients including 51 males and 24 females, who underwent resection of their primary HCC in the Department of Hepatobiliary Surgery at the First Affiliated Hospital of Xi'an Jiaotong University during January 2009 to December 2011. Patients did not receive any preoperative chemotherapy or embolization.

Patients' demographic and clinicopathologic data were obtained through a review of hospital records. And disease recurrence and survival information was updated at each follow-up visit. The time between the surgery date and first disease recurrence date was calculated as disease-free survival (DFS). The time between the diagnostic biopsy and surgery date to death or last follow-up was determined as overall survival (OS) duration.

Cell culture

The human immortalized normal hepatocyte cell line (LO2) and six HCC cell lines (HepG2, MHCC97L, Hep3B, SMMC-7721, MHCC97H, and Huh7) were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China. All cells were cultured in complete Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) containing 10 % fetal bovine serum (FBS; Gibco) with 100 units/mL penicillin and 100 µg/mL streptomycin (Sigma, St. Louis, MO, USA) in a humidified incubator containing 5 % CO₂ at 37 °C.

Cell transfection

Three *TUSC7*-specific small interfering RNAs (siRNAs), the *TUSC7*-siControl (Table 1), pcDNA3.1-*TUSC7* (pcDNA/*TUSC7*), and pcDNA3.1-Control (pcDNA/Control), were purchased from Invitrogen (Carlsbad, CA, USA). Four miRNA vectors, including anti-miR-10a, anti-Control, miR-10a, and miR-10a-Control, were purchased from GeneCopoeia (Guangzhou, China). All cell transfection were performed according to the manufacturer's protocol.

Luciferase reporter assay

To search for the miR-10a binding site of *TUSC7*, we used a number of bioinformatics tools (MicroRNA, Mircode, Starbase v2.0, and RNAhybrid). The putative miR-10a target binding

sequence in *TUSC7* and its binding site mutant were synthesized and cloned downstream of the luciferase gene in the pmirGLO luciferase vector (Promega, Madison, WI, USA). Hep3B cells were co-transfected with wild-type or mutated pmirGLO-miR-10a reporter plasmid and pcDNA/Control or pcDNA/*TUSC7* using Lipofectamine 2000 (Invitrogen). After 48 h, the cells were harvested and luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Madison, WI, USA). Firefly luciferase activity was normalized to the Renilla luciferase activity. Results were obtained from three independent experiments performed in triplicate.

RNA extraction and quantitative real-time PCR

Total RNA was extracted from HCC tissues and cell lines using TRIzol (Invitrogen) following the manufacturer's instructions. The RNA levels of *TUSC7* and *EphA4* were determined by quantitative real-time PCR (qRT-PCR) and calculated using the 2^{-ΔΔCt} method, with the Ct values normalized using GAPDH as an internal control. The primers are listed in Table 2. miRNAs were obtained using the mirVana MiRNA Isolation Kit (Ambion, Austin, TX, USA). Mature miR-10a and *U6* snRNA were reversely transcribed using Stem-loop RT Primer with the iScript II RT Kit (Qiagen, Valencia, CA, USA). qRT-PCR was performed using SYBR Green PCR Master Mix (Qiagen) on an ABI 7500 system (Applied Biosystems, USA).

Western blot

Western blot analysis was performed using standard techniques. The following antibodies were used: E-cadherin (3195S, Cell Signaling, Beverly, MA, USA), vimentin (sc-6260, Santa Cruz Biotechnology, Santa Cruz, CA, USA), *EphA4* (SRP00347b, Saierbio, Tianjin, China), and β-actin (sc-47778, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Table 1 *TUSC7*-siRNAs and *TUSC7*-siControl sequences

siRNA	Sequence
<i>TUSC7</i> -siRNA1	Sense: 5'-GGCCAAACCCUCAAUGAAUtt-3' Antisense: 5'-AUUCAUUGAGGGUUUGCCtg-3'
<i>TUSC7</i> -siRNA2	Sense: 5'-GCGCAUUCUCUUAACAATT-3' Antisense: 5'-UUGUUUAAGAGAAUGCGCTT-3'
<i>TUSC7</i> -siRNA3	Sense: 5'-CUGCCCUCCAUUCUAUCUATT-3' Antisense: 5'-UAGAUAGAAUGGAGGGCAGTT-3'
<i>TUSC7</i> -siRNA4	Sense: 5'-GGAGAGAGAUUAUGCUAAGUTT-3' Antisense: 5'-ACUUAAGCAUAUCUCUCCTT-3'
<i>TUSC7</i> -siControl	Sense: 5'-UUCUCCGAACGUGUCACGUTT-3' Antisense: 5'-ACGUGACACGUUCGGAGAATT-3'

Table 2 Primers used in qRT-PCR

Primer name	Sequence (5'-3')
GAPDH	Forward: 5'-CCGGGAAACTGTGGCGTGATGG-3' Reverse: 5'-AGGTGGAGGAGTGGGTGTCGCTGTT-3'
<i>TUSC7</i>	Forward: 5'-CACTGCCTATGTGCACGACT-3' Reverse: 5'-AGAGTCCGGCAAGAAGAACA-3'
E-cadherin	Forward: 5'-GCCGCTGGCGTCTGTAGGAA-3' Reverse: 5'-TGACCACCGCTCTCCTCCGA-3'
Vimentin	Forward: 5'-GAGAACTTTGCCGTTGAAGC-3' Reverse: 5'-GCTTCCTGTAGGTGGCAATC-3'
<i>EphA4</i>	Forward: 5'-ATGGATCTGTTGCCCTCAC-3' Reverse: 5'-CAGAATTCCTCTACCTTACC-3'

Wound healing assays

To determine cell motility, HCC cells were seeded into six-well plates and grown to 80–90 % confluence. A 200- μ L sterile plastic tip was used to create a wound line across the surface of plates, and cellular debris was removed by washing with phosphate-buffered saline (PBS). Cells were cultured in DMEM in a humidified incubator with 5 % CO₂ at 37 °C for 48 h, and then images were taken with a phase-contrast microscope.

Transwell assays

The 8 μ M pore-size transwell inserts (Nalge Nunc, Penfield, New York, NY, USA) were coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) at 1:8 dilution on the inner layer. Hep3B and MHCC97H cells were resuspended with reduced serum DMEM, and the density was adjusted to 2.5×10^5 /mL 48 h after transfection. A 200- μ L cell suspension was added into the upper chamber, and 750 μ L DMEM containing 10 % FBS was added into the lower chamber and then incubated for 24 h.

Cells were fixed in 4 % paraformaldehyde for 2 min and then permeabilized in 100 % methanol for 20 min. The cells on the inner layer were softly removed with a cotton swab, and the adherent cells on the undersurface of the insert were stained with 0.3 % crystal violet dye for 15 min. The filters were washed with PBS, and

images were taken. Cells on undersurface were counted under a light microscope.


Immunohistochemistry

Immunohistochemistry staining was performed on paraformaldehyde-fixed paraffin sections. The sections were dewaxed and dehydrated. Following rehydration and antigen retrieval in citrate buffer, endogenous peroxidase activity was blocked for 10 min using 3.0 % hydrogen peroxide. The sections were blocked for 30 min using 10 % goat plasma and then separately incubated with the primary antibodies diluted against E-cadherin (1:400) and vimentin (1:200) at 4 °C overnight. The primary antibody was detected using biotinylated secondary antibodies (Golden Bridge Biotechnology, Zhongshan, China) according to the manufacturer's recommendations. The sections were visualized with diaminobenzidine and counterstained with hematoxylin and then dehydrated in alcohol and xylene and mounted on glass slides.

Statistical analysis

Results are presented as mean \pm SD. The SPSS statistical package for Windows version 13 (SPSS, Chicago, IL, USA) and GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA) were used for the Pearson chi-square

Fig. 1 The expression levels of *TUSC7* in HCC. Comparing differences in the expression levels of *TUSC7* between **a** HCC and matched non-tumor tissues, **b** aggressive and non-aggressive tumor tissues, **c** HCC tissues arising from recurrent and non-recurrent groups, and **d** HCC cell lines and the immortalized hepatocyte cell line LO2. Values are depicted as mean \pm SD; * $p < 0.05$ by *t* test



test, a two-tailed Student's *t* test, a Kaplan-Meier plot, a log-rank test, or an ANOVA where appropriate. Differences were considered to be significant when $p < 0.05$.

Results

The expression of *TUSC7* was decreased in HCC

First, we examined the lncRNA *TUSC7* expression level in 75 paired HCC tissues and adjacent non-tumor tissues by qRT-PCR and normalized them to GAPDH. Our results showed that *TUSC7* levels were significantly decreased in HCC tissues compared with adjacent non-tumor tissues ($p < 0.05$, Fig. 1a). HCC cases with at least one of the clinicopathological features, including intrahepatic spreading, venous infiltration, or tumor invasion, tend to be considered as aggressive HCC tissues. When compared with non-aggressive HCC tissues, *TUSC7* levels were markedly downregulated in aggressive HCC tissues ($p < 0.001$, Fig. 1b). Furthermore, *TUSC7* levels were notably lower in tumor tissues arising from patients with tumor recurrence than that without tumor recurrence ($p < 0.001$, Fig. 1c). Then, expression levels of *TUSC7* in HCC cells were determined by qRT-PCR. Our experiments showed that *TUSC7* expression was significantly downregulated in all HCC cell lines when compared with that in LO2 cells ($p < 0.05$, Fig. 1d). These data suggest that *TUSC7* was frequently downregulated in HCC, especially in those patients with metastases and recurrence, suggesting that *TUSC7* might be associated with migration and metastasis of HCC cells.

Clinical significance of *TUSC7* expression in HCC

To determine whether *TUSC7* expression is associated with clinicopathological features in HCC patients, HCC patients were divided into two different groups according to the median level of *TUSC7* expression. Further analysis showed that the expression level of *TUSC7* was significantly correlated with tumor nodes ($p < 0.001$), venous infiltration ($p = 0.017$), Edmondson-Steiner grading ($p = 0.003$), and tumor-node-metastasis (TNM) tumor stage ($p = 0.004$) (Table 3). Thus, our results demonstrated that the reduced expression of *TUSC7* was correlated with poor prognostic features of HCC.

Kaplan-Meier survival curves further revealed that patients with lower *TUSC7* expression had a significantly reduced OS and DFS than those with high *TUSC7* expression ($p < 0.05$, respectively, Fig. 2a, b). Moreover, multivariate Cox proportional hazard regression analysis indicated that venous infiltration and *TUSC7* expression

Table 3 Correlation between the clinicopathologic characteristics and expression of *TUSC7* in HCC

Characteristics	Total no. of patients ($n = 75$)	No. of patients		<i>p</i>
		<i>TUSC7</i> ^{high}	<i>TUSC7</i> ^{low}	
Age (year)				
<50	19	8	11	0.362
≥50	56	29	27	
Gender				
Male	51	27	24	0.466
Female	24	10	14	
HBV				
Absent	55	26	29	0.346
Present	20	11	9	
Serum AFP level (ng/mL)				
<400	18	11	7	0.309
≥400	57	30	27	
Tumor size (cm)				
<5	43	22	21	0.366
≥5	32	12	19	
No. of tumor nodes				
1	46	28	12	<0.001***
≥2	35	9	26	
Cirrhosis				
Absent	55	28	27	0.651
Present	20	9	11	
Venous infiltration				
Absent	54	22	32	0.017*
Present	21	15	6	
Edmondson-Steiner grading				
I + II	49	18	31	0.003**
III + IV	26	19	7	
TNM tumor stage				
I + II	43	15	28	0.004**
III + IV	32	22	10	

HBV hepatitis B virus, AFP alpha-fetoprotein, TNM tumor-node-metastasis

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

were independent prognostic factors for predicting both 3-year OS and DFS in HCC patients ($p = 0.007$ and 0.015 , respectively, Table 4). The data implied that *TUSC7* may be a promising prognostic or progression marker for HCC.

TUSC7 inhibits the migration and invasion of HCC cells

To explore the biological significance of *TUSC7* in HCC progression, we manipulated *TUSC7* levels in HCC cells and examined the alteration of the metastatic behavior of HCC cells. Firstly, we used *TUSC7*-siRNAs (*TUSC7*-siRNA1, *TUSC7*-siRNA2, and *TUSC7*-siRNA3) to downregulate the expression of *TUSC7* in Hep3B cells. Additionally, pcDNA/*TUSC7* vector and pcDNA/




Fig. 2 Prognostic significance of *TUSC7* in HCC cases. Kaplan-Meier 3-year **a** overall and **b** disease-free survival curves of HCC patients according to the level of *TUSC7* expression. The low *TUSC7* group (≤ 0.33 , $n = 53$); the high *TUSC7* group (> 0.33 , $n = 22$). The mean

expression value (0.33) obtained for *TUSC7* of the 75 HCC samples detected by qRT-PCR was chosen as the cutoff value. $p < 0.05$, by log-rank test

Control vector were transfected into MHCC97H cells. The result of qRT-PCR revealed that *TUSC7*-siRNA3 was the most effective siRNA which inhibited the expression of *TUSC7* in Hep3B cells significantly ($p < 0.05$, Fig. 3a). Then, we found that downregulation of *TUSC7* resulted in increased migration and invasion of Hep3B cells (Figs. 3b and 4a). Conversely, the pcDNA/*TUSC7* vector significantly upregulated the levels of *TUSC7* in MHCC97H cells ($p < 0.05$, Fig. 3a) and resulted in diminished migration and invasion of MHCC97H cells (Figs. 3c and 4b). These data indicated that *TUSC7* can inhibit migration and invasion of HCC cells.

TUSC7 suppresses EMT in HCC

It is well recognized that EMT plays a critical role in HCC cell migration and invasion [37]. Therefore, we explored whether *TUSC7* had effects on EMT of HCC. Firstly, we respectively analyzed the correlation of expression levels of *TUSC7* and E-cadherin as well as *TUSC7* and vimentin in 75 paired HCC tissues and adjacent non-tumor tissues by immunohistochemical staining. We found that E-cadherin expression was

distinctly repressed and vimentin expression was notably increased in the low *TUSC7* tissues group compared to that in the high group (Fig. 5(a–d)). Moreover, the results were confirmed by qRT-PCR in HCC tissues (Fig. 5(e, f)) and western blot in HCC cells (Fig. 5(g)). Therefore, we conclude that *TUSC7* inhibited EMT in HCC.

miR-10a is a downstream target of *TUSC7*

As we have mentioned before, recent studies show that *TUSC7* may function as a competing endogenous RNA (ceRNA) or a molecular sponge by modulating the biological functions and concentration of miRNAs in cancers [20, 38]. To investigate the potential downstream miRNAs of *TUSC7* and their interactions in HCC, bioinformatics tools (MicroRNA, Mircode, Starbase v2.0, and RNAhybrid) were used to analyze the potential complementary base pairing between *TUSC7* and miRNAs. The result revealed that dozens of miRNA binding sites were present in *TUSC7* (data not shown). We found that miR-10a contained the complementary sequence of *TUSC7* (Fig. 6a). Additionally, our results have shown that *TUSC7* could repress EMT progression of HCC (Fig. 5(a–g)) and miR-10a has been reported to facilitate EMT


Table 4 Multivariate Cox regression analysis of 3-year overall and disease-free survival of 75 HCC patients

Variables	Overall survival			Disease-free survival		
	HR	95 % CI	<i>p</i>	HR	95 % CI	<i>p</i>
No. of tumor nodules	0.801	0.347, 1.853	0.605	0.598	0.256, 1.400	0.236
Venous infiltration	0.259	0.101, 0.665	0.005**	0.303	0.121, 0.759	0.011*
TNM tumor stage	1.105	0.278, 4.399	0.887	1.089	0.280, 4.230	0.902
<i>TUSC7</i> expression	3.411	1.392, 8.357	0.007**	2.928	1.227, 6.985	0.015*
Edmondson-Steiner grading	1.905	0.837, 4.338	0.125	1.660	0.727, 3.792	0.229

HR hazard ratio, CI confidence interval

* $p < 0.05$; ** $p < 0.01$

Fig. 3 Wound healing assays to assess the effect of *TUSC7* on cell mobility. **a** qRT-PCR analysis revealed that *TUSC7* expression in Hep3B cells was reduced most obviously by *TUSC7*-siRNA3 and pcDNA/*TUSC7* largely increased the *TUSC7* expression in MHCC97H cells. **b** Wound healing assays to assess the effect of *TUSC7* on cell mobility in Hep3B cells. **c** Wound healing assays to assess the effect of *TUSC7* on cell mobility in MHCC97H cells. * $P < 0.05$, by t test



in Hep3B [32], we then focused on miR-10a. To further investigate whether miR-10a was a functional target of *TUSC7*, the dual-luciferase reporter assay was performed. We found that co-transfection of pcDNA/*TUSC7* and miR-10a-WT strongly decreased the luciferase activity while co-transfection of pcDNA/Control and miR-10a-WT did not change the luciferase activity (Fig. 6b), suggesting that miR-10a was a target of *TUSC7*. In parallel, we constructed a reporter plasmid where the *TUSC7* seed region binding site was mutated (miR-10a-Mut) to test binding specificity (Fig. 6a). Consequently, co-

transfection of pcDNA/*TUSC7* and miR-10a-Mut did not change luciferase activity (Fig. 6b). Thus, these results demonstrated that *TUSC7* could directly bind to miR-10a at the miRNA recognition site.

To further confirm whether *TUSC7* exerted its function through miR-10a, we determined the expression levels of miR-10a in Hep3B cells transfected with *TUSC7*-siRNA3 and in MHCC97H cells transfected with pcDNA/*TUSC7*. The qRT-PCR results revealed that miR-10a expression was visibly elevated in Hep3B cells transfected with *TUSC7*-




Fig. 4 Transwell assays to assess the effect of *TUSC7* on migration and invasion in HCC cells. **a** The effect of *TUSC7* on migration and invasion ability in Hep3B cells. **b** The effect of *TUSC7* on migration and invasion ability in MHCC97H cells. * $P < 0.05$, by *t* test

siRNA3 and clearly reduced in MHCC97H cells transfected with pcDNA/*TUSC7* (Fig. 6c, d, respectively). It has been reported that miR-10a could promote EMT in HCC through the miR-10a/*EphA4* axis [32]. Our data showed that ectopic expression of *TUSC7* could affect the messenger RNA (mRNA) levels of *EphA4* in HCC cells (Fig. 6e, f), which further confirmed that miR-10a is a target of *TUSC7* in HCC. Taken together, these data suggest that *TUSC7* might suppress EMT through the *TUSC7*-miR-10a-*EphA4* axis in HCC.

miR-10a reverses the inhibitory effects of *TUSC7* in HCC cells

Although our experiments had confirmed that miR-10a was a target of *TUSC7*, the function of miR-10a in *TUSC7*-induced

inhibition in HCC cells remained unclear. And in order to confirm whether *TUSC7* could suppress EMT through the *TUSC7*-miR-10a-*EphA4* axis, the further experiments were performed. Wound healing assays (Fig. 7a–d) and Transwell assays (Fig. 7f–i) showed that miR-10a could largely reverse the inhibitory effect of *TUSC7* on HCC cell migration and invasion. Western blot also revealed that the inhibition of *EphA4* protein expression and EMT by *TUSC7* could be largely reversed by miR-10a (Fig. 7e). These results indicated that miR-10a could reverse the inhibitory effects of *TUSC7* in HCC cells and *TUSC7* could suppress EMT through the *TUSC7*-miR-10a-*EphA4* axis.

Discussion

HCC patients currently have a poor prognosis, and it is without doubt that early detection and treatment could




Fig. 5 *TUSC7* inhibited EMT progression in HCC tissues. **a–d** Immunohistochemistry staining of E-cadherin and vimentin in HCC tissues. In cases of high *TUSC7* expression tissue group (**a, b**), there was strong E-cadherin and no detectable vimentin protein expression in the same tissue section. In contrast, in the cases of low *TUSC7* expression tissue group (**c, d**), there was no detectable E-cadherin and strong vimentin protein expression. Values are depicted as mean ± SD; ** $p < 0.001$, by t test. Scale bar = 100 μ m. **e, f** Expression of EMT


mRNA markers was assessed by qRT-PCR in the low *TUSC7* expression tissue group (≤ 0.33 , $n = 38$) and high *TUSC7* expression tissues group (> 0.33 , $n = 37$), both groups from HCC samples. **g** Hep3B and MHCC97H cells with different *TUSC7* levels were subjected to western blot for E-cadherin and vimentin. Representative western blot showed that downregulation of *TUSC7* obviously increased protein expression of vimentin and reduced E-cadherin expression in HCC cells. * $P < 0.05$, by t test

significantly increase their chances of survival. Recently, lncRNAs have shown great therapeutic potential for human diseases, including HCC [39]. For example, studies from Yuan SX et al. have revealed that *DANCR* increases stemness and serves as a potential prognostic marker, and a therapeutic target, for HCC [40]. Research from Chen CL et al. unveiled the molecular mechanisms of how *PTENP1* repressed the tumorigenic properties of HCC cells and demonstrated the potential of the *SB-BV* hybrid vector for *PTENP1* lncRNA modulation and HCC therapy [41]. Accordingly, *TUSC7* was identified as a robust suppressor of cancer [21]. In this study, we found that *TUSC7* expression in HCC was significantly down-regulated. *TUSC7* expression in HCC tissues was negatively associated with more tumor nodes, more venous infiltration,

advanced Edmondson-Steiner grading, and advanced TNM tumor stage. Moreover, comparison of Kaplan-Meier survival curves indicated that patients with lower *TUSC7* expression in HCC tissues had notably worse prognosis. *TUSC7* was also confirmed to be an independent risk factor for HCC patients. Altogether, these clinical data suggest strongly that *TUSC7* is critical for prognosis determination in HCC patients. Furthermore, we tested the action of *TUSC7* on tumor invasion and metastasis of HCC cells by taking different approaches and found that *TUSC7* inhibited cell invasion and metastasis in HCC.

EMT, a dynamic and reversible cellular process, is characterized by a loss of cell polarity and intracellular junctions and acquirement of mesenchymal features, which could result in


Fig. 6 *TUSC7* targets miR-10a. **a** *TUSC7* binding sequence in miR-10a-WT and sequence of miR-10a-Mut. **b** *TUSC7* overexpression significantly suppressed the luciferase activity that carried wild-type but not mutant-type miR-10a. And *TUSC7* overexpression almost had no effect on the luciferase activity that carried neither wild-type nor mutant-type miR-10a. *n* = three repeats with similar results; ***p* < 0.01, by *t* test. **c, d** qRT-PCR revealed that *TUSC7* could negatively regulate miR-10a expression; **e, f** qRT-PCR revealed that *TUSC7* could positively regulate the mRNA expression level of *EphA4*. **P* < 0.05, by *t* test



increased HCC cell migration and invasion [42]. Recent studies showed that lncRNAs may play critical roles in the EMT progress not only in HCC but also in other cancers [43–45]. Furthermore, it has been found that some lncRNAs could promote EMT [45, 46] while some could restrain EMT [47, 48]. For example, *lncRNA-UCAL* has been shown to act as an HCC tumor suppressor by enhancing vimentin degradation and suppressing EMT progress [47]. Overexpression of *lncRNA-UCAL* induced EMT and increased the migratory and invasive abilities of bladder cancer cells [49]. *lncRNA-ATB* may also act on colon tumorigenesis by suppressing E-cadherin expression and promoting EMT [50]. In this study, we analyzed EMT biomarkers of HCC tissues by using immunohistochemistry and qRT-PCR and those of HCC cells by western blot. Then, we determined the expression of an epithelial marker (E-cadherin) and mesenchymal marker (vimentin) in HCC with either low or high *TUSC7* expression. Interestingly, it was found that *TUSC7* expression was positively associated with E-cadherin expression and negatively associated with vimentin expression in HCC. We concluded that *TUSC7* could suppress EMT in HCC.

Growing evidence suggests that lncRNA may act as a ceRNA to regulate miRNAs in cancer progression [51]. As we have stated before, *TUSC7* acts as a tumor suppressor in human cancers by interacting with miRNAs, such as miR-23b [20] and miR-211 [38]. It has been reported that miR-10a could facilitate cell migration, invasion, and EMT by directly targeting the 3'-UTR of *EphA4* transcript to reduce its expression in HCC [32]. *EphA4* could inhibit cell migration and invasion by regulating the EMT process through the β 1-integrin signaling pathway [32]. Hence, combining our previous results and the bioinformatics analysis, we focused on miR-10a and its downstream target *EphA4*. Our results showed that miR-10a was indeed a downstream target of *TUSC7*. We found that acting as a sponge of miR-10a,

Fig. 7 miR-10a reverses the inhibitory effects of *TUSC7* on HCC cells. **a–d** Wound healing assays showed that miR-10a largely reversed the inhibitory effect of *TUSC7* on cell mobility. **e** Western blot revealed that miR-10a largely reversed the inhibitory effect of *TUSC7* on EMT. **f–i** Transwell assays showed that miR-10a could largely reverse the inhibitory effect of *TUSC7* on cell migration and invasion. * *P* < 0.05, ***P* < 0.01, ****P* < 0.001, by *t* test



TUSC7 could therefore directly interact with miR-10a to restrain its function. Thus, when the expression level of *TUSC7* was reduced, its inhibition on miR-10a would be attenuated. The expression level of miR-10a would then be increased, which could lead to decreased expression of *EphA4*. Therefore, we have confirmed that the downregulation of *TUSC7* could enhance miR-10a expression to reduce *EphA4* expression, thereby promoting migration, invasion, and EMT in HCC, at least in part.

In summary, our data indicate that *TUSC7* may function as a tumor suppressor in HCC. Mechanistically, our experimental data demonstrate that targeting the *TUSC7*-miR-10a-*EphA4* axis may represent a novel therapeutic application in HCC.

Acknowledgments This work was supported by the Fundamental Research Funds for the Central Universities (No. XJJ2010010), the Natural Science Foundation of Shaanxi Province in China (Grant No. 2014JM4103), the National Natural Scientific Foundation of China (No. 81402039, 81272645 and 81572847), and the Clinical Innovation Funds for 7-year-postgraduate by the First Affiliated Hospital of XJTU (Grant No. 15ZD14).

Compliance with ethical standards This study was reviewed and approved by the Research Ethics Committee of the Xi'an Jiaotong University. All patients provided informed consent before surgery. All samples were handled according to the ethical and legal standards.

Conflicts of interest None

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer Clin.* 2011;61(2):69–90. doi:10.3322/caac.20107.
- Forner A, Llovet JM, Guiti J. Hepatocellular carcinoma. *Lancet.* 2012;379(9822):1245–55. doi:10.1016/S0140-6736(11)61347-0.
- El-Ser HB. Hepatocellular carcinoma. *N Engl J Med.* 2011;365(2):118–27. doi:10.1056/NEJMra1001683.
- Guo S, Turdean S, Kovacs A, Contac AO, Jung I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update. *World J Clin Cases.* 2015;3(5):393–404. doi:10.12998/wjcc.v3.i5.393.
- Bottoni P, Isgro MA, Scatena R. The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research. *Expert Rev Proteomics.* 2016;13(1):115–33. doi:10.1586/14789450.2016.1112742.
- Zuo J, Wen J, Lei M, Wen M, Li S, Lv X, et al. Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT. *Med Oncol.* 2016;33(2):15. doi:10.1007/s12032-015-0716-6.
- Li H, Xu F, Li S, Zhong A, Meng X, Lai M. The tumor microenvironment: an irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis. *Cell Adhes Migr.* 2016. doi:10.1080/19336918.2015.1129481.
- Matouk IJ, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A. The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. *Oncotarget.* 2015. doi:10.18632/oncotarget.6387.
- Jun JH, Joo CK. MicroRNA-124 controls transforming growth factor beta1-induced epithelial-mesenchymal transition in the retinal pigment epithelium by targeting RHOG. *Invest Ophthalmol Vis Sci.* 2016;57(1):12–22. doi:10.1167/iov.15-17111.
- Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. *Cell.* 2011;145(2):178–81. doi:10.1016/j.cell.2011.06.014.
- Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. *PLoS One.* 2015;10(10):e0141041. doi:10.1371/journal.pone.0141042.
- Chen S, Shao C, Xu M, Ji J, Xie Y, Lei Y, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-coding RNA HUCA1. *Int J Clin Exp Pathol.* 2015;8(8):9052–61.
- Liang WC, Fu J, Wang C, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as a sponge in colorectal cancer. *Oncotarget.* 2015;6(26):22511–25.
- Chen Y, Guo J, Chen L, Luo N, Yang W, Qu X. A long noncoding RNA AB0124 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. *Oncotarget.* 2015;6(28):25381–9. doi:10.18632/oncotarget.4541.
- Jun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. *Br J Cancer.* 2014;111(11):2131–41. doi:10.1038/bjc.2014.520.
- Peng Y, Li Z, Li Z. GRP78 secreted by tumor cells stimulates differentiation of bone marrow mesenchymal stem cells to cancer-associated fibroblasts. *Biochem Biophys Res Commun.* 2013;440(4):558–63. doi:10.1016/j.bbrc.2013.09.108.
- Meseure D, Drak Alsibai K, Nicolas A, Bieche I, Morillon A. Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. *BioMed Res Int.* 2015;2015:320214. doi:10.1155/2015/320214.
- Cabanski CR, White NM, Dang HX, Silva-Fisher JM, Rauck CE, Cicka D, et al. Pan-cancer transcriptome analysis reveals long non-coding RNAs with conserved function. *RNA Biol.* 2015;12(6):628–42. doi:10.1080/15476286.2015.1038012.
- Ding YC, Yu W, Ma C, Wang Q, Huang CS, Huang T. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma. *Int J Clin Exp Pathol.* 2014;7(11):8065–70.
- Qi P, Xu MD, Shen XH, Ni SJ, Huang D, Tan C, et al. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. *Int J Cancer J Int du Cancer.* 2015;137(6):1269–78. doi:10.1002/ijc.29516.
- Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. *Cancer Res.* 2010;70(1):160–71. doi:10.1158/0008-5472.CAN-09-1902.
- Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. *J Transl Med.* 2013;11:122. doi:10.1186/1479-5876-11-122.
- Tong YS, Zhou XL, Wang XW, Wu QQ, Yang TX, Lv J, et al. Association of decreased expression of long non-coding RNA

- LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. *J Transl Med*. 2014;12:233. doi:10.1186/s12967-014-0233-y.
24. Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. *J Clin Med*. 2015;4(8):1651–67. doi:10.3390/jcm4081651.
 25. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. *J Med Genetics*. 2015. doi:10.1136/jmedgenet-2015-103334.
 26. Tuo YL, Li XM, Luo J. Long noncoding RNA UCA1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. *Eur Rev Med Pharmacol Sci*. 2015;19(18):3403–11.
 27. Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J, et al. Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. *Mol Ther*. 2015;23(12):1899–911. doi:10.1038/mt.2015.170.
 28. El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, et al. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. *BioMed Res Int*. 2015;2015:649750. doi:10.1155/2015/649750.
 29. Safari A, Seifoleslami M, Yahaghi E, Sedaghati F, Khameneie MK. Upregulation of miR-20a and miR-10a expression levels act as potential biomarkers of aggressive progression and poor prognosis in cervical cancer. *Tumour Biol*. 2015. doi:10.1007/s13277-015-4064-0.
 30. Yu T, Liu L, Li J, Yan M, Lin H, Liu Y, et al. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. *Oncotarget*. 2015;6(30):30239–50. doi:10.18632/oncotarget.4972.
 31. Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang F, et al. miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. *FEBS Lett*. 2015;589(6):756–65. doi:10.1016/j.febslet.2015.02.005.
 32. Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M, et al. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. *Hepatology*. 2015;61(2):667–77. doi:10.1002/hep.26071.
 33. Bourgin C, Murai KK, Richter M, Pasqual EB. The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways. *J Cell Biol*. 2007;178(4):1293–307. doi:10.1083/jcb.200610139.
 34. Giaginis C, Tsoukalas N, Boumakis E, Andriadou P, Kavantzias N, Patsouris E, et al. Ephrin (A) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. *PMC Clin Pathol*. 2014;14(1):8. doi:10.1186/1472-6890-14-8.
 35. Takano H, Nakamae T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, et al. Inhibition of Eph receptor A4 by 2,5-dimethylpoly(aryl)benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. *Oncotarget*. 2015;6(38):74563–76. doi:10.18632/oncotarget.5729.
 36. Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, et al. Adenium: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. *Nat Cell Biol*. 2015;17(12):1607. doi:10.1038/ncb3281.
 37. Ogunwobi OO, Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models. *Crit Rev Oncol Hematol*. 2012;83(3):319–28. doi:10.1016/j.critrevonc.2011.11.007.
 38. Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, et al. LncRNA loc285194 is a p53-regulated tumor suppressor. *Nucleic Acids Res*. 2013;41(9):4976–87. doi:10.1093/nar/gkt182.
 39. Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. *Int J Mol Sci*. 2014;15(11):20434–48. doi:10.3390/ijms151120434.
 40. Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LJ, et al. Long noncoding RNA DANCR increases stemness features in hepatocellular carcinoma by derepression of CTNBN1. *Hepatology*. 2015. doi:10.1002/hep.27893.
 41. Chen CL, Tseng YW, Wu JC, Chen GY, Lin H, Hwang SM, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and microRNA regulation. *Biomaterials*. 2015;44:71–8. doi:10.1016/j.biomaterials.2014.12.023.
 42. Xie B, Lin W, Ye J, Wang X, Wang B, Xiong S, et al. DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1. *J Exp Clin Cancer Res*. 2015;34(1):101. doi:10.1186/s13046-015-0218-6.
 43. Mazzotta A, Partipilo G, De Samma S, Giotta F, Simone G, Mangia A. Nuclear ERP expression and its prognostic significance in breast cancer patients. *Tumour Biol*. 2015. doi:10.1007/s13277-015-4465-0.
 44. Liu H, Li X, Guo E. Knockdown of long noncoding RNA SPRY4-IT1 suppresses glioma cell proliferation, metastasis and epithelial-mesenchymal transition. *Int J Clin Exp Pathol*. 2015;8(8):9140–6.
 45. Lv W, Wang L, Lu J, Mu J, Liu Y, Dong P. Long noncoding RNA HAA0125 potentiates cell migration and invasion in gallbladder cancer. *BioMed Res Int*. 2015;2015:108458. doi:10.1155/2015/108458.
 46. Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. *Int J Clin Exp Pathol*. 2015;8(5):4881–91.
 47. Wang TH, Lin YS, Chen Y, Yeh CT, Huang YL, Hsieh TH, et al. Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition. *Oncotarget*. 2015;6(27):23342–57. doi:10.18632/oncotarget.4344.
 48. Han Y, Ye J, Wu D, Wu P, Chen Z, Chen J, et al. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. *BMC Cancer*. 2014;14:932. doi:10.1186/1471-2407-14-932.
 49. Xue M, Pang H, Li X, Li H, Pan J, Chen W. Long noncoding RNA UCA1 promotes bladder cancer cell migration and invasion via hsa-miR-145/ ZEB1/2 /FSCN1 pathway. *Cancer Sci*. 2015. doi:10.1111/cas.12844.
 50. Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. *J Gastroenterol Hepatol*. 2015. doi:10.1111/jgh.13206.
 51. Bischof O, Martinez-Zamudio RI. MicroRNAs and lncRNAs in senescence: a re-view. *IUBMB Life*. 2015;67(4):255–67. doi:10.1002/iub.1373.